Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2018-12-21 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
First patient with colorectal cancer dosed in the Phase ll study of birinapant in combination with Keytruda®
Regulatory Filings Classification · 94% confidence The document is a press release from Medivir AB announcing that the first patient has been dosed in the Phase II study of birinapant in combination with Keytruda for colorectal cancer. It details the study design, endpoints, and provides context about the drug and the collaboration. This type of announcement, focusing on clinical trial progress and scientific updates, is typically classified as an Investor Presentation (IP) if it were a deck, or often falls under general Regulatory Filings (RNS) or sometimes an Earnings Release (ER) if tied to quarterly results. However, since it is a specific, non-financial, operational update about clinical trial progress and drug development, and does not fit the strict definitions of ER (key highlights only), IR (comprehensive quarterly report), or CT (transcript), the most appropriate category for a specific operational/scientific update that isn't a formal regulatory report is often RNS, as it is an announcement made pursuant to the EU Market Abuse Regulation. Given the content is highly specific to drug development progress, it is a significant operational update. Since there is no specific 'Clinical Trial Update' code, RNS serves as the best fit for a mandatory regulatory announcement that isn't a standard financial filing.
2018-12-21 English
The transformation into a company focused on clinical development of pharmaceuticals has now been completed and Medivir gives a project update
Regulatory Filings Classification · 92% confidence The document is a press release from Medivir AB announcing the completion of a corporate transformation, significant staff reductions, and providing detailed updates on its clinical development projects (Remetinostat, Birinapant, MIV-818, MIV-711). It includes forward-looking statements regarding FDA discussions, Phase II commencement timelines (Q1 2019), and Phase Ia results (Q2 2019). The concluding statement, "This is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation," strongly suggests this is a mandatory disclosure of material, non-public information. Since it focuses on operational changes and project status rather than just preliminary financial figures (ER) or a full annual review (10-K), it best fits the category for general regulatory announcements or updates that don't fit elsewhere. Given the content is a comprehensive operational and pipeline update, it is most closely aligned with an Earnings Release (ER) if it were periodic, but since it's a strategic operational update, and not a standard quarterly report (IR) or a formal presentation (IP), the most appropriate general category for significant, non-standard corporate news that must be disclosed is Regulatory Filings (RNS), as it is a broad disclosure mandated by regulation.
2018-12-14 English
Omorganisationen till renodlat kliniskt läkemedelsutvecklingsbolag genomförd och Medivir lämnar projektuppdatering
Management Reports Classification · 99% confidence The document is a press release from Medivir AB detailing an internal reorganization (reducing staff to focus on clinical development projects) and providing specific updates on their clinical drug pipeline (Remetinostat, Birinapant, MIV-818, MIV-711). It concludes with a statement that the information is required to be made public under EU market abuse regulation and specifies the release time. This content structure—company news, project updates, and regulatory disclosure boilerplate—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses heavily on operational changes and pipeline progress rather than just summarizing period-end financial figures (which would be ER), and it's not a full quarterly report (IR) or a transcript (CT), it fits best as an Earnings Release (ER) which often includes operational highlights alongside financial context, or potentially a Regulatory Filing (RNS) if it were less detailed. Given the depth of the project updates, ER is the most appropriate fit for a company providing operational and pipeline news outside of a formal quarterly filing.
2018-12-14 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to September 2018. It contains detailed financial summaries (income statements, cash flow, balance sheet items), management commentary ('Vd har ordet'), and operational updates on R&D projects. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2018
2018-10-26 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY – SEPTEMBER 2018' and contains comprehensive financial summaries, including net turnover, EBITDA, earnings per share, and cash flow for the specified period. It also includes a CEO's message, detailed R&D project updates, and pipeline tables. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2018
2018-10-26 English
Medivir drar ner på forskningen för att fokusera på klinisk utveckling
Legal Proceedings Report Classification · 99% confidence The document is a press release from Medivir AB announcing strategic changes, including focusing on clinical development, cost reductions, and layoffs. Crucially, it announces that the CEO will hold a conference call for investors, analysts, and media tomorrow to discuss the developments and the path forward. The text provides dial-in numbers and a link to follow the call. This structure—an announcement followed by details for an upcoming investor/analyst call—is characteristic of an Earnings Release (ER) or a general corporate update that precedes a detailed discussion. Since the content focuses on strategic shifts and cost control rather than specific quarterly financial figures (which would suggest ER or IR), and it explicitly announces a conference call where management will present and comment, it strongly aligns with the purpose of an Earnings Release (ER) or a related investor event announcement. Given the context of strategic operational changes and the immediate scheduling of a call to discuss the 'latest developments' and 'path forward,' ER is the most appropriate fit among the options, as these announcements often precede or accompany the formal release of results/strategy updates. However, since it is primarily an operational announcement that *leads into* a call, and not the transcript or the full financial report itself, it functions as a high-level announcement. If the call were an earnings call, this would be the precursor. Given the options, ER (Earnings Release) is the closest fit for a major operational/strategic announcement that immediately schedules a management presentation.
2018-10-17 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.